BIOMIMETIC GLUCOSE BINDING MOLECULES
Our mission is to help people with diabetes to live more normal and longer lives. We are using our proprietary Biomimetic Glucose Binding Molecules (GBM) to develop a new glucose sensor chemistry that will enable market-leading Continuous Glucose Monitors (CGM).
Our GBMs offer unparalleled selectivity towards glucose and function in even the most complex biological mixtures.
STABLE & VERSATILE
Our GBMs are extremely robust with a multi-year operational potential.
Carbometrics’ GBMs are produced by a streamlined, scalable synthesis and are readily derivatised for bioconjugation and chemical synthesis.
Carbometrics is a specialist supramolecular chemistry company based in Bristol, UK. Our core competency is the design, synthesis and derivatisation of highly selective and robust synthetic small molecule receptors. Our principle technology is the world’s most selective Glucose Binding Molecule (GBM) which is supported by over 20 years of cutting-edge research pioneered by Professor Anthony Davis’ group at the University of Bristol, UK. Carbometrics was spun-out after the founders sold their first company Ziylo to Novo Nordisk. With Carbometrics’ support, Novo Nordisk is using the GBM technology to develop a cutting-edge insulin – Glucose Sensitive Insulin (GSI). Alongside our goal to support this highly innovative project, Carbometrics’ goal is to exploit the GBM technology further by developing it to create highly robust and accurate glucose sensing platform that can be used to create market-leading Continuous Glucose Monitoring (CGM) sensors.